S Xiao

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint ZNF198-FGFR1 transforming activity depends on a novel proline-rich ZNF198 oligomerization domain
    S Xiao
    Department of Pathology, Brigham and Women s Hospital, The Dana Farber Cancer Institute, and the Division of Hematology Oncology, Children s Hospital, Boston
    Blood 96:699-704. 2000
  2. ncbi request reprint FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome
    S Xiao
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Nat Genet 18:84-7. 1998
  3. ncbi request reprint PLAG1 fusion oncogenes in lipoblastoma
    M K Hibbard
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer Res 60:4869-72. 2000
  4. ncbi request reprint KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
    B P Rubin
    Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
    Cancer Res 61:8118-21. 2001
  5. ncbi request reprint Insulin receptor activation in solitary fibrous tumours
    Y Li
    Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Pathol 211:550-4. 2007
  6. pmc TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors
    B Lawrence
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Pathol 157:377-84. 2000
  7. ncbi request reprint UTRN on chromosome 6q24 is mutated in multiple tumors
    Y Li
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Oncogene 26:6220-8. 2007

Collaborators

Detail Information

Publications7

  1. ncbi request reprint ZNF198-FGFR1 transforming activity depends on a novel proline-rich ZNF198 oligomerization domain
    S Xiao
    Department of Pathology, Brigham and Women s Hospital, The Dana Farber Cancer Institute, and the Division of Hematology Oncology, Children s Hospital, Boston
    Blood 96:699-704. 2000
    ..Blood. 2000;96:699-704)..
  2. ncbi request reprint FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome
    S Xiao
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Nat Genet 18:84-7. 1998
    ..Our studies demonstrate an FGFR1 oncogenic role and suggest a tumorigenic mechanism in which ZNF198-FGFR1 activation results from ZNF198 zinc-finger-mediated homodimerization...
  3. ncbi request reprint PLAG1 fusion oncogenes in lipoblastoma
    M K Hibbard
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer Res 60:4869-72. 2000
    ..Our findings reveal that PLAG1 activation, presumably resulting from transcriptional up-regulation, is a central oncogenic event in lipoblastoma...
  4. ncbi request reprint KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
    B P Rubin
    Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
    Cancer Res 61:8118-21. 2001
    ..These studies underscore the role of KIT activation in GIST pathogenesis, and they suggest that activated KIT might represent a universal therapeutic target in GISTs...
  5. ncbi request reprint Insulin receptor activation in solitary fibrous tumours
    Y Li
    Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Pathol 211:550-4. 2007
    ..The aetiological relevance of IGF-2 is supported by expression of IR-A, the IR isoform with high affinity for IGF-2, in all SFTs. Our studies suggest that IR activation plays an oncogenic role in SFTs...
  6. pmc TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors
    B Lawrence
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Pathol 157:377-84. 2000
    ..Notably, a TPM3-ALK oncogene was reported recently in anaplastic lymphoma, and TPM3-ALK is thereby the first known fusion oncogene that transforms, in vivo, both mesenchymal and lymphoid human cell lineages...
  7. ncbi request reprint UTRN on chromosome 6q24 is mutated in multiple tumors
    Y Li
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Oncogene 26:6220-8. 2007
    ..Overexpression of a wild-type UTRN in breast cancer cells inhibited tumor cell growth in vitro and reduced their tumor potential in nude mice. Our studies suggest that UTRN is a candidate tumor suppressor gene...